-
公开(公告)号：US11702468B2
公开(公告)日：2023-07-18
申请号：US16554510
申请日：2019-08-28
申请人： UCB Pharma, S.A.
发明人： David G. Winkler , Jiye Shi , John Latham
IPC分类号： G01N33/68 , G01N33/50 , G01N33/577 , C07K16/22 , C07K14/51 , C07K16/18 , A61K47/64 , C07K14/475
CPC分类号： C07K16/22 , A61K47/643 , A61K47/646 , C07K14/475 , C07K14/51 , C07K16/18 , G01N33/6854 , C07K2317/76 , G01N33/50 , G01N33/577 , G01N33/68 , G01N33/6863 , G01N2333/4704
摘要： Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
-
公开(公告)号：US20220289832A1
公开(公告)日：2022-09-15
申请号：US17750444
申请日：2022-05-23
申请人： UCB PHARMA, S.A.
摘要： The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
-
公开(公告)号：US11427650B2
公开(公告)日：2022-08-30
申请号：US16124650
申请日：2019-01-21
申请人： UCB PHARMA S.A.
摘要： The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号：US09828438B2
公开(公告)日：2017-11-28
申请号：US15058460
申请日：2016-07-06
申请人： UCB PHARMA S.A.
CPC分类号： C07K16/468 , C07K16/00 , C07K16/18 , C07K16/245 , C07K2317/24 , C07K2317/31 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/569 , C07K2317/64 , C07K2317/92
摘要： The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
-
公开(公告)号：US09550973B2
公开(公告)日：2017-01-24
申请号：US15083446
申请日：2016-03-29
申请人： UCB PHARMA, S.A.
发明人： Mark Ellis , David Paul Humphreys
CPC分类号： C12N1/20 , C07K16/241 , C07K16/244 , C07K2317/14 , C07K2317/20 , C07K2317/55 , C12N9/52 , C12N15/70 , C12P21/02 , C12R1/19 , Y02P20/52
摘要： A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
摘要翻译： 包含一个或多个以下突变蛋白酶基因的重组革兰氏阴性细菌细胞：a）突变的Tsp基因，其中突变的Tsp基因编码具有降低的蛋白酶活性的Tsp蛋白或是敲除突变的Tsp基因; b）突变的ptr基因，其中突变的ptr基因编码具有降低的蛋白酶活性的蛋白酶III蛋白质或是敲除突变的ptr基因; 和c）编码具有伴侣活性和降低的蛋白酶活性的DegP蛋白的突变DegP基因; 其中所述细胞与野生型细菌细胞是同基因的，除了突变的Tsp基因和/或突变的ptr基因和/或突变的DegP基因和任选的编码目的蛋白质的多核苷酸序列。
-
公开(公告)号：US20160185761A1
公开(公告)日：2016-06-30
申请号：US14909246
申请日：2014-07-28
申请人： UCB PHARMA, S.A.
发明人： Florian Montel , Eric Jnoff
IPC分类号： C07D403/06
CPC分类号： C07D403/06
摘要： The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
摘要翻译： 本发明涉及2-氧代-1-吡咯烷基三唑衍生物，其制备方法，含有它们的药物组合物及其作为用于增强认知功能或抵抗认知衰退的药物的用途。
-
-
-
公开(公告)号：US08895714B2
公开(公告)日：2014-11-25
申请号：US13049087
申请日：2011-03-16
CPC分类号： C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
摘要翻译： 公开了含有至少一种衍生自对人CD22具有特异性的小鼠单克隆抗体的CDR的抗体分子。 还公开了CDR移植抗体，其中至少一个CDR是修饰的CDR。 进一步公开的是编码抗体分子，载体，转化的宿主细胞的权利要求的DNA序列和抗体分子在治疗由表达CD22的细胞介导的疾病中的用途。
-
公开(公告)号：US20140342406A1
公开(公告)日：2014-11-20
申请号：US14285721
申请日：2014-05-23
申请人： UCB PHARMA S.A.
发明人： Helene Margaret Finney , Terence Seward Baker , Alastair David Griffiths Lawson , Karen Margrete Miller , Marc Roger de Ryck , Christian Gilbert J. Wolff
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K39/3955 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
摘要： A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
摘要翻译： 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。
-
-
-
-
-
-
-
-
-
搜索结果
330 条记录 (耗时 0.03 秒)
